Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease

被引:37
作者
Prince, GA
Denamur, F
Deschamps, M
Garçon, N
Prieels, JP
Slaoui, M
Thiriart, C
Porter, DD
机构
[1] Virion Syst Inc, Rockville, MD 20850 USA
[2] SmithKline Beecham Biol SA, B-1330 Rixensart, Belgium
[3] Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA
关键词
adjuvants; alveolitis; Sigmodon hispidus;
D O I
10.1016/S0264-410X(00)00417-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The mechanisms by which administration of a formalin-inactivated respiratory syncytial virus vaccine resulted in enhanced disease among children after they later became naturally infected with the virus remains largely undefined. After immunization and live virus challenge, the cotton rat demonstrated the histopathologic marker of the enhanced disease, polymorphonuclear leukocyte infiltration of lung alveolar spaces. We now report that immunization with formalin-inactivated vaccine formulated with the adjuvant, 3-deacylated monophosphoryl lipid A, dramatically reduces or eliminates the polymorphonuclear leukocyte infiltration within the alveoli of cotton rats post-challenge. We suggest, that this or similar adjuvants may be beneficial components of candidate non-replicating respiratory syncytial virus vaccines, whose development has been hampered by safety concerns. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2048 / 2054
页数:7
相关论文
共 40 条
  • [1] Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines
    Bastien, N
    Trudel, M
    Simard, C
    [J]. VACCINE, 1999, 17 (7-8) : 832 - 836
  • [2] Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides
    Cano, F
    Plotnicky-Gilquin, H
    Nguyen, TN
    Liljeqvist, S
    Samuelson, P
    Bonnefoy, JY
    Ståhl, S
    Robert, A
    [J]. VACCINE, 2000, 18 (24) : 2743 - 2752
  • [3] INFLUENCE OF IMMUNOLOGICAL FACTORS IN RESPIRATORY SYNCYTIAL VIRUS DISEASE - OF LOWER RESPIRATORY TRACT
    CHANOCK, RM
    KAPIKIAN, AZ
    MILLS, J
    KIM, HW
    PARROTT, RH
    [J]. ARCHIVES OF ENVIRONMENTAL HEALTH, 1970, 21 (03): : 347 - &
  • [4] FIELD EVALUATION OF A RESPIRATORY SYNCYTIAL VIRUS VACCINE AND A TRIVALENT PARAINFLUENZA VIRUS VACCINE IN A PEDIATRIC POPULATION
    CHIN, J
    MAGOFFIN, RL
    SHEARER, LA
    SCHIEBLE, JH
    LENNETTE, EH
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1969, 89 (04) : 449 - +
  • [5] Connor E, 1997, PEDIATRICS, V99, P93
  • [6] COLD PASSAGED, TEMPERATURE-SENSITIVE MUTANTS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) ARE HIGHLY ATTENUATED, IMMUNOGENIC, AND PROTECTIVE IN SERONEGATIVE CHIMPANZEES, EVEN WHEN RSV ANTIBODIES ARE INFUSED SHORTLY BEFORE IMMUNIZATION
    CROWE, JE
    BUI, PT
    SIBER, GR
    ELKINS, WR
    CHANOCK, RM
    MURPHY, BR
    [J]. VACCINE, 1995, 13 (09) : 847 - 855
  • [7] Dreizin R S, 1971, Vopr Virusol, V16, P670
  • [8] A PROTOTYPE RECOMBINANT VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS AND PARAINFLUENZA VIRUS TYPE-3
    DU, RP
    JACKSON, GED
    WYDE, PR
    YAN, WY
    WANG, QJ
    GISONNI, L
    SANHUEZA, SE
    KLEIN, MH
    EWASYSHYN, ME
    [J]. BIO-TECHNOLOGY, 1994, 12 (08): : 813 - 818
  • [9] Respiratory syncytial virus vaccines
    Dudas, RA
    Karron, RA
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 1998, 11 (03) : 430 - +
  • [10] RESPIRATORY VIRUS IMMUNIZATION .I. A FIELD TRIAL OF 2 INACTIVATED RESPIRATORY VIRUS VACCINES - AN AQUEOUS TRIVALENT PARAINFLUENZA VIRUS VACCINE AND AN ALUM-PRECIPITATED RESPIRATORY SYNCYTIAL VIRUS VACCINE
    FULGINITI, VA
    ELLER, JJ
    SIEBER, OF
    JOYNER, JW
    MINAMITANI, M
    MEIKLEJOHN, G
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1969, 89 (04) : 435 - +